SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Core Insights - SAB Biotherapeutics, Inc. has advanced its lead candidate SAB-142 into the registrational Phase 2b SAFEGUARD study, with multiple patients already dosed and enrollment expected to complete by the end of 2026, with topline data anticipated in the second half of 2027 [1][3][7] - The company raised $175 million in an oversubscribed private placement to fully fund the SAFEGUARD study, indicating strong investor confidence [1][11] - SAB-142 has shown a favorable safety profile in Phase 1 clinical data, with no serum sickness and low immunogenicity observed across all cohorts [1][7][11] Financial Highlights - For the fiscal year 2025, SAB reported a net income of $13.3 million, a significant improvement from a net loss of $34.1 million in 2024 [13] - The company had cash, cash equivalents, and available-for-sale securities totaling $143.5 million as of December 31, 2025, providing operational runway through 2028 [13] - Research and development expenses for 2025 were $34.4 million, compared to $30.3 million in 2024, reflecting ongoing investment in clinical development [13] Clinical Development - SAB-142 is being developed as a disease-modifying immunotherapy for type 1 diabetes (T1D), with the potential to delay disease progression [1][11][14] - The Phase 1 study results confirmed that SAB-142 does not cause serum sickness and has low/no immunogenicity, supporting its chronic dosing in outpatient settings [7][11] - The company has activated multiple clinical trial sites in the U.S., Australia, and New Zealand for the SAFEGUARD study [7] Leadership and Governance - David Zaccardelli, Pharm.D., was appointed as Chair of the Board of Directors in January 2026, bringing over 20 years of biopharmaceutical experience [6] - Rita Jain, M.D., was also appointed as an Independent Director in January 2026, adding expertise in biopharmaceutical development and regulatory affairs [11]